1-10 of 10
Thomas Kipps
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Sustained Responses Following Ibrutinib Discontinuation after Frontline Therapy with Obinutuzumab Plus Ibrutinib in Patients with Chronic Lymphocytic Leukemia

Paula A. Lengerke Diaz, MD, Michael Y. Choi, MD, Eider F. Moreno Cortes, MD, Jose V. Forero, MD, Juliana Velez-Lujan, PhD, Carlos I. Amaya-Chanaga, MD, Thomas Kipps, MDPhD, Januario E. Castro, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-143473
Published: 2020
Journal Articles

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Thomas Kipps, MD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4404.
https://doi.org/10.1182/blood-2018-99-117175
Published: 2018
Journal Articles

Interim Results for the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia (CC-5013-CLL-009 Study)

Clemens Wendtner, MD, Graeme Fraser, Stuart L. Goldberg, MD, Adrian JC Bloor, PhD, FRCP, FRCPath, Stephan Stilgenbauer, Florence Cymbalista, Thomas Kipps, Brendan Purse, Jennie Zhang, Jay Mei, MD, PhD, Asher Chanan-Khan
Journal: Blood
Blood (2011) 118 (21): 2859.
https://doi.org/10.1182/blood.V118.21.2859.2859
Published: 2011
Journal Articles

Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry

Jeff Sharman, MD, Christopher R Flowers, MD, Mark Weiss, MD, David Grinblatt, MD, Charles Farber, MD, PhD, Neil Kay, MD, Thomas Kipps, MD, Nicole Lamanna, MD, Chris Pashos, PhD, Ian W Flinn, MD, Mark Kozloff, MD, Susan Lerner, MS, Arlene S Swern, PhD, Kristen A Sullivan, MBA, Thomas K. Street, RPh, Michael Keating, MBBS
Journal: Blood
Blood (2011) 118 (21): 2864.
https://doi.org/10.1182/blood.V118.21.2864.2864
Published: 2011
Journal Articles

Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis,

Liguang Chen, MD, PhD, George Chen, B.S., Jessie-Farah Fecteau, Ph.D., Greg Coffey, PhD, Charles Prussak, PhD, Dennis A. Carson, MD, Thomas Kipps, MD
Journal: Blood
Blood (2011) 118 (21): 3875.
https://doi.org/10.1182/blood.V118.21.3875.3875
Published: 2011
Journal Articles

Subnetwork-Based Analysis of Chronic Lymphocytic Leukemia Identifies Pathways That Associate with Disease Progression,

Han-Yu Chuang, Laura Z. Rassenti, Ph.D., Michelle Salcedo, BS, Kate Licon, Alexander Kohlmann, PhD, Torsten Haferlach, MD, Robin Foa, Trey Ideker, PhD, Thomas Kipps
Journal: Blood
Blood (2011) 118 (21): 3564.
https://doi.org/10.1182/blood.V118.21.3564.3564
Published: 2011
Journal Articles

IRF4 mutations in chronic lymphocytic leukemia

Brief Report
Violaine Havelange, Yuri Pekarsky, Tatsuya Nakamura, Alexey Palamarchuk, Hansjuerg Alder, Laura Rassenti, Thomas Kipps, Carlo M. Croce
Journal: Blood
Blood (2011) 118 (10): 2827–2829.
https://doi.org/10.1182/blood-2011-04-350579
Published: 2011
Journal Articles

13q14 deletions in CLL involve cooperating tumor suppressors

Alexey Palamarchuk, Alexey Efanov, Natalya Nazaryan, Urmila Santanam, Hansjuerg Alder, Laura Rassenti, Thomas Kipps, Carlo M. Croce, Yuri Pekarsky
Journal: Blood
Blood (2010) 115 (19): 3916–3922.
https://doi.org/10.1182/blood-2009-10-249367
Published: 2010
Journal Articles

Phase I study of obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia

Clinical Trials & Observations
Susan M. O'Brien, David F. Claxton, Michael Crump, Stefan Faderl, Thomas Kipps, Michael J. Keating, Jean Viallet, Bruce D. Cheson
Journal: Blood
Blood (2009) 113 (2): 299–305.
https://doi.org/10.1182/blood-2008-02-137943
Published: 2009
Journal Articles

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Katherine I. Lin, MBBS, BND, Constantine S. Tam, MBBS, Lynne V. Abruzzo, MD, William Wierda, MD, Lynn Barron, Susan O’Brien, MD, Thomas Kipps, MD, Laura Rassenti, PhD, Susan Lerner, MS, Hagop Kantarjian, MD, Michael J. Keating, MD
Journal: Blood
Blood (2007) 110 (11): 753.
https://doi.org/10.1182/blood.V110.11.753.753
Published: 2007